Poster contest

Congratulations to the 4 winners of the poster contest!

These winners received a price of 1.500 euro – 1.000 euro, 750 euro and 500 euro, kindly offered by

 

Nora Sundahl Ghent University Hospital, Ghent, Belgium & Cancer Research Institute Ghent (CRIG), Ghent, Belgium Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: clinical and translational results
Elise De Bleser Ghent University Hospital, Ghent, Belgium Stereotactic body radiotherapy and elective nodal radiotherapy as a metastasis-directed treatment for nodal oligorecurrent prostate cancer: multi-institutional analysis
Carole Mercier Center for Oncological Research (CORE), University of Antwerp, Belgium & Iridium Kankernetwerk, Antwerp, Belgium Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Bert Dhondt Ghent University Hospital & Ghent University & Cancer Research Institute Ghent (CRIG) Exploration of the urinary proteome in the search for new biomarkers for prostate cancer:  a promising role for extracellular vesicles

Research grant

Congratulations to the research grant winner!

This winner received a price of 10.000 euro, kindly offer by

 

 

 

Bert Dhondt Ghent University Hospital Lab-on-a-chip Based Extracellular Vesicle Detection to Diagnose Early Stage Urological Cancers

Overview submitted posters

1. Stereotactic body radiotherapy and elective nodal radiotherapy as a metastasis-directed treatment for nodal oligorecurrent prostate cancer: multi-institutional analysis

Elise De Bleser, Ghent University Hospital, Ghent, Belgium

2. FGF- R inhibition, a biomarker driven alternative in second line metastatic urothelial cancer

Daan De Maeseneer, Ghent University Hospital, Ghent, Belgium

3. Ethnic Paradigm in Prostate Cancer – does it really matter?

Tania De Oliveira E Silva, CHU Saint Pierre, Brussels, Belgium

 

4. Exploration of the urinary proteome in the search for new biomarkers for prostate cancer: a promising role for extracellular vesicles

Bert Dhondt, Ghent University Hospital, Ghent, Belgium & Ghent University, Ghent Belgium & Cancer Research Institute Ghent (CRIG), Ghent, Belgium

5. Do CHAARTED and LATITUDE impact our daily clinical practice regarding systemic treatment for newly diagnosed metastatic, hormone-sensitive prostate cancer?

Stéphanie Hollebosch, Ghent University Hospital, Ghent, Belgium

6. Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival.

Carole Mercier, Center for Oncological Research (CORE), University of Antwerp, Belgium & Iridium Kankernetwerk, Antwerp, Belgium

7. Retrospective analysis of patient characteristics and sequencing of radium-223 within real-life clinical setting

 Dirk Schrijvers, ZNA Middelheim, Antwerp, Belgium

8. Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: clinical and translational results

Nora Sundahl, Ghent University Hospital, Ghent, Belgium & Cancer Research Institute Ghent (CRIG), Ghent, Belgium

9. Interference of abiraterone acetate in serum testosterone assessment.

Alice Van Goethem, GZA Sint-Augustinus, Antwerp, Belgium & Iridium Kankernetwerk, Antwerp, Belgium

10.Early biomarkers for TKI-induced renal damage in mRCC patients

Tijl Vermassen, Ghent University Hospital, Ghent, Belgium